These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11277412)

  • 1. Standardization in immunohistochemistry.
    O'Leary TJ
    Appl Immunohistochem Mol Morphol; 2001 Mar; 9(1):3-8. PubMed ID: 11277412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
    Hicks DG; Kulkarni S
    Am J Clin Pathol; 2008 Feb; 129(2):263-73. PubMed ID: 18208807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.
    ; Torlakovic EE; Riddell R; Banerjee D; El-Zimaity H; Pilavdzic D; Dawe P; Magliocco A; Barnes P; Berendt R; Cook D; Gilks B; Williams G; Perez-Ordonez B; Wehrli B; Swanson PE; Otis CN; Nielsen S; Vyberg M; Butany J
    Am J Clin Pathol; 2010 Mar; 133(3):354-65. PubMed ID: 20154273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry.
    Hsu FD; Nielsen TO; Alkushi A; Dupuis B; Huntsman D; Liu CL; van de Rijn M; Gilks CB
    Mod Pathol; 2002 Dec; 15(12):1374-80. PubMed ID: 12481020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reference image-based method for optimization of clinical immunohistochemistry.
    Kap M; Lam KH; Ewing-Graham P; Riegman P
    Histopathology; 2015 Aug; 67(2):193-205. PubMed ID: 25640638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab.
    Rhodes A; Borthwick D; Sykes R; Al-Sam S; Paradiso A
    Am J Clin Pathol; 2004 Jul; 122(1):51-60. PubMed ID: 15272530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories.
    Ramos-Vara JA; Kiupel M; Baszler T; Bliven L; Brodersen B; Chelack B; Czub S; Del Piero F; Dial S; Ehrhart EJ; Graham T; Manning L; Paulsen D; Valli VE; West K;
    J Vet Diagn Invest; 2008 Jul; 20(4):393-413. PubMed ID: 18599844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control in immunohistochemistry. Report of a workshop sponsored by the Biological Stain Commission.
    Elias JM; Gown AM; Nakamura RM; Wilbur DC; Herman GE; Jaffe ES; Battifora H; Brigati DJ
    Am J Clin Pathol; 1989 Dec; 92(6):836-43. PubMed ID: 2480062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumab.
    Jasani B; Miller K
    Am J Clin Pathol; 2005 Feb; 123(2):314; author reply 314-5. PubMed ID: 15842059
    [No Abstract]   [Full Text] [Related]  

  • 11. [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
    Penault-Llorca F; Jacquemier J; Le Doussal V; Voigt JJ
    Ann Pathol; 1999 Sep; 19(4):280-2. PubMed ID: 10544761
    [No Abstract]   [Full Text] [Related]  

  • 12. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is standardization possible in immunohistochemical examination?].
    Kaczorowski S; Kaczorowska M
    Patol Pol; 1992; 43(1):10-5. PubMed ID: 1296167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique.
    Ramos-Vara JA; Miller MA
    Vet Pathol; 2014 Jan; 51(1):42-87. PubMed ID: 24129895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial.
    von Wasielewski R; Mengel M; Wiese B; Rüdiger T; Müller-Hermelink HK; Kreipe H
    Am J Clin Pathol; 2002 Nov; 118(5):675-82. PubMed ID: 12428786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICSH guidelines for the standardization of bone marrow immunohistochemistry.
    Torlakovic EE; Brynes RK; Hyjek E; Lee SH; Kreipe H; Kremer M; McKenna R; Sadahira Y; Tzankov A; Reis M; Porwit A;
    Int J Lab Hematol; 2015 Aug; 37(4):431-49. PubMed ID: 25977137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 testing in breast cancer using parallel tissue-based methods.
    Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
    JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical detection of HER2 protein and its evaluation in breast carcinoma: comparative study of two methods (HercepTest DAKO versus the routine immunohistochemical approach with the DAKO polyclonal antibody) and the results from two laboratories].
    Dvorácková J; Uvírová M; Kerlínová V; Kodet R; Mrhalová M
    Cesk Patol; 2002; 38 Suppl 1():20-6. PubMed ID: 12677893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
    Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
    J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardization in immunohistology.
    Leong AS; Leong TY
    Methods Mol Biol; 2011; 724():37-68. PubMed ID: 21370005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.